Stockreport

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TScan Therapeutics, Inc.  (TCRX) 
PDF Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual [Read more]